Bryan Roberts

Polaris Partners is an Independent Venture Capital firm founded in 1996 by Stephen D. Arnold, Jonathan A. Flint and Terrance G. McGuire. Polaris Partners is headquartered in Waltham.

Kindex Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on discovering and developing of novel therapeutics for the treatment of metabolic. The company is headquartered in Boston, MA.

Faraday Pharmaceuticals, Inc. engages in the research and development of elemental reducing agents (ERAs). Its therapeutic agents have potential applications for treatment of critical care illnesses. The company was founded by Mark B. Roth and Christopher Toombs in 2014 and is headquartered in Seattle, WA.

Camp4 Therapeutics Corp. operates as a biotechnology company. The firm discovers a treatment option for patients. The company was founded by Paulina Hill and Leonard Zon on May 20, 2016 and is headquartered in Cambridge, the United Kingdom.

The Capital Network, Inc. is a private company based in Wellesley, MA that provides founder-focused fundraising education programs. The company aims to create a more inclusive and accessible funding ecosystem to support female and other first-time founders of early stage startups. The company offers three programs: the Fellowship for Female Founders, Fundraising Readiness Workshops, and the Investment and Inclusion Series. The Fellowship for Female Founders is a six-month program that has helped over 90+ female founders raise over $85m in capital. The company also offers ongoing workshops for first-time startup founders and a series of honest conversations to bring about meaningful systemic change. The Capital Network has a network of 300+ investors and sponsors who help them make the fundraising ecosystem work for everybody. The company was founded by Ashkan Afkhami and Chula Reynolds.

Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts.

IFM Therapeutics LLC engages in the development and transformation of immunotherapy for patients with serious diseases. It focuses on developing small molecule drugs that target the innate immune system. The company was founded by Gary D. Glick, Luigi Franchi, Matthias Geyer, Eicke Latz, and Anthony W. Opipari, Jr. in 2015 and is headquartered in Boston, MA.